Cite

    Menter, A., Arenberger, P., Balser, S., Beissert, S., Cauthen, A., Czeloth, N., Soung, J., Jazayeri, S., Weisenseel, P., & Jayadeva, G. (2021). similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study. Expert opinion on biological therapy, 21, 87–96. http://access.bl.uk/ark:/81055/vdc_100118546619.0x00001a